ICICI QIP | Singapore central bank largest investor, nets 11% of Rs 15,000 crore issue

The Monetary Authority of Singapore, Morgan Stanley Investment Management and French bank Societe Generale were the top three investors

The Monetary Authority of Singapore - the city-state’s central bank - is the largest investor in ICICI Bank’s qualified institutional placement (QIP) issue, which concluded on August 15.

The Monetary Authority of Singapore picked up 4.6 crore shares for Rs 1,662 crore – more than 11 percent of the Rs 15,000 crore QIP issue, The Times of India reported.

The second-largest investor is Morgan Stanley Investment Management, which put in Rs 1,086 crore and French bank Societe Generale which invested Rs 832 crore (2.3 crore shares), it added.

ICICI Bank on August 15 said it had completed the allotment of equity shares through QIP, and raised close to Rs 15,000 crore (~$2 billion). The private lender issued 418,994,413 equity shares at an issue price of Rs 358 apiece, the bank informed the exchanges.

“The proceeds of the issue will be used towards strengthening the capital adequacy ratio of the bank, improving the bank’s competitive positioning and/or general corporate requirements or any other purposes as may be permissible under the applicable law and approved by the Board of Directors of the bank or its duly constituted committee,” the statement read.

This is not an uncommon move from Singapore, which through its central bank and investment arm GIC has gone big on the Indian capital markets and last invested Rs 900 crore in Zee Entertainment (ZEEL).

Indian private lenders have so far raised over Rs 50,000 crore through equity issues amid the COVID-19 pandemic.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...

SD Solutions

Search This Blog